<DOC>
	<DOC>NCT00258622</DOC>
	<brief_summary>Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.</brief_summary>
	<brief_title>NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Age &gt;18 years Neuropathic pain and allodynia after a peripheral nerve injury (VAS &gt;= 4) Patients who cannot cooperate and do no understand Danish Fertile women Clinically significant abnormality or disease Drug and alcohol abuse Clinically abnormal ECG Hypersensitivity to any of the treatments Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics except gabapentin, anticoagulants, Na channel blockers and beta blockers Patients who have previously been treated in a NS1209 study Patients treated with an investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Peripheral neuropathic pain</keyword>
	<keyword>Neuropathic pain</keyword>
	<keyword>Chronic pain</keyword>
</DOC>